| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/09/2003 | WO2003002745A2 The cage gene of actinobacillus actinomycetemcomitans, the protein it encodes and uses thereof |
| 01/09/2003 | WO2003002742A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | WO2003002739A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 01/09/2003 | WO2003002737A1 Novel human topoisomerase 2α inhibitory protein and utilization thereof |
| 01/09/2003 | WO2003002602A2 Nogo and nogo receptor derived peptides for t-cell mediated neuroprotection |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002155A1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002069A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | WO2003002068A2 Diagnosis and treatment of cancer |
| 01/09/2003 | WO2003002067A2 Inhibition of tumor growth and metastasis by n5 gene |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003001983A2 Methods for diagnosing and treating a disease mediated by decreased mmp-2 function |
| 01/09/2003 | WO2002092825A3 Retroviral vectors for gene therapy |
| 01/09/2003 | WO2002092795A3 Intracellular bonding of costimulatory molecules |
| 01/09/2003 | WO2002089727A9 Methods of using cytokine c17 |
| 01/09/2003 | WO2002083707A9 Tub antisense constructs |
| 01/09/2003 | WO2002078630A8 Tub 3'-variant |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002013855A3 Vaccines containing ribavirin and methods of use thereof |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001097828A3 Rhob as a suppressor of cancer cell growth and cell transformation |
| 01/09/2003 | WO2001092512A3 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides |
| 01/09/2003 | WO2001090390A9 Use of baculovirus vectors in gene therapy |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001070776A3 Nimr compositions and their methods of use |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | WO2001053504A9 Replication deficient adenovirus vectors |
| 01/09/2003 | US20030009019 Novel telomerase |
| 01/09/2003 | US20030008839 Use of a dimethyldialkylammonium salt as an adjuvant for a nucleic acid vaccine |
| 01/09/2003 | US20030008836 Eukaryotic gene expression cassette and uses thereof |
| 01/09/2003 | US20030008824 Stimulation of vascularization with VEGF-B |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008818 Compositions containing inclusion complexes |
| 01/09/2003 | US20030008399 Controlling viral replication or gene expression in a cell; obtain cell infected with virus, transform with nucleotide sequence expressng preferential replicases, monitor viral gene expression |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008391 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008376 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008375 Generation of preferential adenoviral expression vector; obtain cells, infect with virus, harvest and lyse cell, recover vectors |
| 01/09/2003 | US20030008374 Methods and compositions relating to improved lentiviral vectors and their applications |
| 01/09/2003 | US20030008357 Polypeptide for use in the treatment of inflammation, rheumatoid arritis, psoriasis, and diabetic retinopathy |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008346 MMSC1 - an MMAC1 interacting protein |
| 01/09/2003 | US20030008342 Vaccine for use in the treatment and prevention of cancer, autoimmune disease, human viral infections |
| 01/09/2003 | US20030008284 Polynucleotides related to colon cancer |
| 01/09/2003 | US20030008279 Cells for use in the diagnosis and treatment of viral diseases |
| 01/09/2003 | US20030008274 Nucleotide sequences coding polypeptide for use in the treatment of and prevention of viral diseases |
| 01/09/2003 | US20030007977 Vaccine containing amino acid |
| 01/09/2003 | US20030007976 Anticancer agents; sensitivity to Mycobacterium |
| 01/09/2003 | US20030007975 Anticancer agents |
| 01/09/2003 | US20030007969 Administering integrin antagonist |
| 01/09/2003 | US20030007952 Polypeptides |
| 01/09/2003 | CA2452202A1 Diagnostic methods and agents |
| 01/09/2003 | CA2451959A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | CA2451850A1 Medicinal compositions |
| 01/09/2003 | CA2451816A1 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | CA2451739A1 Hcv e1e2 vaccine compositions |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451218A1 Diagnosis and treatment of cancer |
| 01/08/2003 | EP1273666A1 Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
| 01/08/2003 | EP1273660A2 Human sodium-hydrogen exchanger like protein 1 |
| 01/08/2003 | EP1273658A1 Novel protein, dna thereof and process for producing the same |
| 01/08/2003 | EP1273657A1 Novel protein, process for producing the same and use thereof |
| 01/08/2003 | EP1273309A1 Gene therapeutic method for the treatment of GnRH-receptor positve carcinomas through GnRH induced tumor cell specific activation of a therapeutic gene, corresponding nucleic acids and vectors |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272665A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/08/2003 | EP1272663A2 Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications |
| 01/08/2003 | EP1272652A2 Herpes viruses for immune modulation |
| 01/08/2003 | EP1272636A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 01/08/2003 | EP1272635A1 Cryptic-like secreted protein |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272625A2 CpG REDUCED PLASMIDS AND VIRAL VECTORS |
| 01/08/2003 | EP1272615A2 Osteocalcin promoter directed adenovirus replicaton for therapy |
| 01/08/2003 | EP1272614A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 01/08/2003 | EP1272610A1 Mutant bank |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272513A2 Neurogenic compositions and methods |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272502A2 Dna molecules and polypeptides of pseudomonas syringae hrp pathogenicity island and their uses |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |
| 01/08/2003 | EP1066061A4 Use of scatter factor to enhance angiogenesis |
| 01/08/2003 | EP1005358B1 Use of a neurturin protein product for preventing and treating hearing loss |
| 01/08/2003 | EP0728194B1 In situ modification and manipulation of stem cells of the central nervous system |
| 01/08/2003 | EP0607309B1 The regulation of systemic immune responses utilizing cytokines and antigens |
| 01/08/2003 | CN1390257A Transfer compounds, the production and the use thereof |
| 01/08/2003 | CN1390141A Nucleic acid-containing complex |
| 01/08/2003 | CN1389269A Compound of polypeptide-liposome and human vascular endothelial growth factor gene recombination plasmid and its use |